US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
You may also be interested in...
A US bipartisan Senate bill and House proposal aim to bring pharma manufacturing from China to closer to home, through partnerships with American universities to train the workforce and develop technologies.
BARDA and Development Financing Corp. officials provide insights into window of opportunity for partnering on manufacturing scale-up.
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.